DAVE CHOKSHI is assistant vice president at New York City Health + Hospitals, where he leads the Office of Ambulatory Care Transformation. He is a primary care internist at Bellevue Hospital and is an assistant professor of population health and medicine at NYU Langone Medical Center. Previously, he was an internal medicine resident at Brigham & Women's Hospital in Boston.
Dave graduated summa cum laude and Phi Beta Kappa from Duke University with a double-major in Chemistry and Public Policy. He was awarded a Rhodes Scholarship in 2002, reading for an M.Sc. in Global Health Sciences and an M.Sc. in Comparative Health Policy during his two years at the University of Oxford.
Dave was elected as a Faculty Scholar at Duke University, the highest academic honor at Duke. He also served as Chairman of the Honor Council, as Editor-in-Chief of Vertices, the science magazine, and was a Howard Hughes Research Fellow in molecular immunology while at Duke. Dave's interest in public health and health policy led him to pursue summer internships at the Louisiana Department of Health, the U.S. Department of Health and Human Services, and with a nonprofit organization working to improve the health status of women and children in a red-light district in Mumbai, India. At Oxford he also helped organize MalariaGEN, a consortium of scientists and laboratories spanning the globe which investigates the genetic epidemiology of malaria susceptibility.
While in medical school at Penn, supported by a full-tuition merit scholarship, Dave has worked with the nonprofit Universities Allied for Essential Medicines (UAEM), dedicated to improving access to medicines in developing countries. Dave served as acting Executive Director of UAEM, raising over $200,000 in funds from the Ford and Rockefeller Foundations and hiring the group's first permanent full-time staff. At Penn, he also completed clinical experiences in Guatemala, Peru, Ghana, Botswana, and India.
Dave has written broadly on public health topics in peer-reviewed journals including JAMA, BMJ, PLoS Medicine, Health Affairs, and Nature. Most recently, Dave has begun a project to implement risk prediction tools in cardiology, working with the clinical software company Proventys.